|Table of Contents|

Clinical analysis of HSTCL（4 cases）

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 14
Page:
2691-2694
Research Field:
Publishing date:

Info

Title:
Clinical analysis of HSTCL（4 cases）
Author(s):
SONG Lijun; CHEN Junmin; SU Yan; XUE Yimiao; MA Yanping; BAO Shen; WEI Yuping
People's Hospital of Ningxia Hui Autonomous Region，First Affiliated Hospital of Northwest University for Nationalities，Ningxia Yinchuan 750002，China．
Keywords:
HSTCL; γδ T cell; αβ T cell; flow cytometry; gene rearrangement
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.14.022
Abstract:
Objective:To investigate the clinical,pathological and immunophenotypic features of hepatosplenic T-cell lymphoma (HSTCL).Methods:From September 2014 to December 2021,the clinical data of 4 patients with hepatosplenic T-cell lymphoma (HSTCL) in our hospital were analyzed retrospectively.Results:Of the 4 patients,3 were male and 1 was female.The average age at diagnosis was 55 years.All patients had splenomegaly,and 3 patients had bone marrow involvement,all of the 4 patients were diagnosed as HSTCL by spleen biopsy and/or bone marrow immunophenotyping.Among them,2 cases were γδ,1 case was αβ,1 case was indeterminate subtype,4 cases were complicated with TCR gene rearrangement,one patient was complicated with chromosome 7 abnormality,and the average time from clinical symptoms to diagnosis was 10.3 months.Conclusion:T-cell lymphoma of liver and spleen is one of the most common T-cell lymphomas in elderly patients,and it is easy to be misdiagnosed and missed in clinic,immunophenotype is an important index for definite diagnosis of bone marrow involvement,and this type of lymphoma presents aggressive progression and poor prognosis.

References:

［1］PRO B,ALLEN P,BEHDAD A.Hepatosplenic T-cell lymphoma:a rare but challenging entity ［J］.Blood,2020,136(18):2018-2026.
［2］HORWITZ SM,ANSELL S,AI WZ,et al.NCCN guidelines insights:T-cell lymphomas,version 1.2021［J］.Journal of the National Comprehensive Cancer Network,2020,18(11):1460-1467.
［3］RAHMAN K,GUPTA T,GUPTA R,et al.Hepatosplenic T-cell lymphoma diagnosed using flow cytometry.A single-center study of 12 cases from North India ［J］.Journal of Cancer Research and Therapeutics,2022,18(4):1093-1097.
［4］YABE M,MIRANDA RN,MEDEIROS LJ.Hepatosplenic T-cell Lymphoma:a review of clinicopathologic features,pathogenesis,and prognostic factors ［J］.Human Pathology,2018,74:5-16.
［5］DU J,LU G,XU B,et al.Identification of key genes and pathways associated with hepatosplenic T-cell lymphoma (HSTCL) by bioinformatics analysis ［J］.Clinical Laboratory,2021,67(5).doi:10.7754/Clin.Lab.2020.201018.
［6］SONG W,ZHANG H,YANG F,et al.Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression［J］.Cellular Oncology (Dordrecht),2023,46(1):211-226.
［7］YABE M,MEDEIROS LJ,TANG G,et al.Prognostic factors of hepatosplenic T-cell lymphoma:Clinicopathologic study of 28 cases ［J］.American Journal of Surgical Pathology,2016,40(5):676-688.
［8］BRON D,DE LEVAL L,MICHIELS S,et al.Hepatosplenic T-cell lymphoma:treatment challenges ［J］.Current Ppinion in Oncology,2021,33(5):406-411.
［9］KLEBANER D,KOURA D,TZACHANIS D,et al.Intensive induction therapy compared with CHOP for hepatosplenic T-cell lymphoma［J］.Clinical Lymphoma Myeloma & Leukemia,2020,20(7):431-437.e2.
［10］CORAZZELLI G,CAPOBIANCO G,RUSSO F,et al.Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas［J］.Haematologica,2005,90(3):ECR14.
［11］JAEGER G,BAUER F,BREZINSCHEK R,et al.Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine ［J］.Annals of Oncology,2008,19(5):1025-1026.
［12］JENNIFER CZ,SARA MOHAMED J,SALMA A,et al.Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ［J］.Expert Review of Hematology,2020,13(6):577-583.
［13］COIFFIER B,FEDERICO M,CABALLERO D,et al.Therapeutic options in relapsed or refractory peripheral T-cell lymphoma［J］.Cancer Treatment Reviews,2014,40(9):1080-1088.
［14］VISNYEI K,GROSSBARD ML,SHAPIRA I.Hepatosplenic γδ T-cell lymphoma:an overview ［J］.Clinical Lymphoma Myeloma & Leukemia,2013,13(4):360-369.
［15］LI Y,CHEN K,ZUO C,et al.Survival analysis of hepatosplenic T cell lymphoma:a population-based study using SEER ［J］.International Journal of General Medicine,2021,14:8399-8411.

Memo

Memo:
宁夏回族自治区人民医院培育振兴项目(编号：201917）
Last Update: 1900-01-01